Employer-mandated high-deductible health plan enrollment was not associated with reduced use of oral targeted anticancer ...
Goad, PharmD, MPH, of Chapman University explains why pharmacists are trusted, accessible sources for COVID-19 vaccine ...
MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, ...
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to ...
FDA authorized frontline pirtobrutinib for previously untreated CLL/SLL without known 17p deletion, expanding use beyond its established relapsed/refractory setting after covalent BTK inhibition.
Michael Wechsler, MD, of National Jewish Health, discusses how twice yearly depemokimab reduces exacerbation risk in patients with T2 asthma. The findings suggest twice yearly dosing may offer early ...
Type 2 (T2)-high and T2-low asthma are distinguishable by unique transcriptomic networks, but characterization of T2-low asthma remains relatively poo ...
Gray market peptides cause vague symptoms patients may not disclose or link, so serious harms can go unnoticed until late, ...
Telitacicept has the first regulatory approval for Sjögren disease (China), while global phase 3 programs aim to support ...
Weekly survodutide 3.6 mg/6.0 mg achieved up to 13.1% mean weight loss at week 76 versus 3.1% with placebo, meeting ...
Without a functioning ACIP, Jeffery Goad, PharmD, MPH, explains who now guides COVID-19 vaccine use and how HMOs can stock ...
A finalized mandatory model will test whether tying Medicare Part B drug rebates to international prices can lower costs for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results